Luke S Vest, Anam Ahmad, Sanhitha Valasareddy, Nancy Phillips, Adam Kilian
{"title":"白细胞介素-6和白细胞介素-17抑制难治性巨细胞动脉炎。","authors":"Luke S Vest, Anam Ahmad, Sanhitha Valasareddy, Nancy Phillips, Adam Kilian","doi":"10.1002/acr2.70094","DOIUrl":null,"url":null,"abstract":"<p><p>Giant cell arteritis (GCA) is a granulomatous vasculitis that can involve both cranial and extracranial vessels. Although interleukin-6 (IL-6) receptor blockade is an established therapy, treatment options for medically refractory disease remain limited. We report a unique case of extracranial GCA refractory to glucocorticoids, azathioprine, tocilizumab (IL-6 inhibitor), and secukinumab (IL-17A inhibitor) that responded robustly to upadacitinib, a selective JAK1 inhibitor. To our knowledge, this is the first reported case of GCA demonstrating resistance to both IL-6 and IL-17 inhibition but clinical and imaging remission with JAK inhibition, highlighting the role of upadacitinib as a therapy for patients with GCA.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 8","pages":"e70094"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305451/pdf/","citationCount":"0","resultStr":"{\"title\":\"Giant Cell Arteritis Refractory to Interleukin-6 and Interleukin-17 Inhibition Treated With Upadacitinib.\",\"authors\":\"Luke S Vest, Anam Ahmad, Sanhitha Valasareddy, Nancy Phillips, Adam Kilian\",\"doi\":\"10.1002/acr2.70094\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Giant cell arteritis (GCA) is a granulomatous vasculitis that can involve both cranial and extracranial vessels. Although interleukin-6 (IL-6) receptor blockade is an established therapy, treatment options for medically refractory disease remain limited. We report a unique case of extracranial GCA refractory to glucocorticoids, azathioprine, tocilizumab (IL-6 inhibitor), and secukinumab (IL-17A inhibitor) that responded robustly to upadacitinib, a selective JAK1 inhibitor. To our knowledge, this is the first reported case of GCA demonstrating resistance to both IL-6 and IL-17 inhibition but clinical and imaging remission with JAK inhibition, highlighting the role of upadacitinib as a therapy for patients with GCA.</p>\",\"PeriodicalId\":93845,\"journal\":{\"name\":\"ACR open rheumatology\",\"volume\":\"7 8\",\"pages\":\"e70094\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305451/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACR open rheumatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/acr2.70094\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACR open rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/acr2.70094","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
Giant Cell Arteritis Refractory to Interleukin-6 and Interleukin-17 Inhibition Treated With Upadacitinib.
Giant cell arteritis (GCA) is a granulomatous vasculitis that can involve both cranial and extracranial vessels. Although interleukin-6 (IL-6) receptor blockade is an established therapy, treatment options for medically refractory disease remain limited. We report a unique case of extracranial GCA refractory to glucocorticoids, azathioprine, tocilizumab (IL-6 inhibitor), and secukinumab (IL-17A inhibitor) that responded robustly to upadacitinib, a selective JAK1 inhibitor. To our knowledge, this is the first reported case of GCA demonstrating resistance to both IL-6 and IL-17 inhibition but clinical and imaging remission with JAK inhibition, highlighting the role of upadacitinib as a therapy for patients with GCA.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
